Content area

|
|

Anvendelse af monoaminooksidase-hæmmeren isocarboxazid ved behandlingsresistent depression

Forfatter(e)
Jens Knud Larsen1, Lene Krogh-Nielsen2 & Kim Brøsen3 1) Afdeling M, Aarhus Universitetshospital, Risskov 2) Psykiatrisk Afdeling Svendborg, Odense Universitetshospital 3) Forskningsenheden for Klinisk Farmakologi, Syddansk Universitet, Odense Ugeskr Læger 2015;177:V06150499
Reference: 
Ugeskr Læger 2015;177:V06150499
Blad nummer: 
Sidetal: 
2-6
The use of the monoamine oxidase inhibitor isocarboxazide in treatment-resistant depression
The antidepressant efficacy of isocarboxazide is well esta­blished; however, the clinical use early became restricted and today the use of isocarboxazide in Denmark is very limited. Isocarboxazide is safe when keeping a low tyra­mine-containing diet and avoiding concomitant treatment with certain drugs. The risk of developing oedema can be reduced by vitamin B6 treatment. Normal dosage isocar­bo­xazide may be prescribed for all patients because isocarbo­xazide is not metabolized through the CYP2D6 enzyme complex like most other antidepressants. It is recommended to include isocarboxazide in the official treatment algorithms for patients who are resistant to conventional antidepres­sant therapy and electroconvulsive therapy.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anna Birthe Holmehøj Bach | 04/12
1 Kommentar
af Susanne L. M. Bülow | 03/12
1 Kommentar
af Andreas Gothardt Lundh | 02/12
1 Kommentar
af Michael Uldall Steinfath | 01/12
1 Kommentar
af Pedram Kazemi-Esfarjani | 01/12
1 Kommentar
af Bjarne Stigsby | 30/11
2 kommentarer
af Camilla Bang | 29/11
2 kommentarer
af Stine Madsen-Østerbye | 29/11
1 Kommentar